Answers are grounded in this paper and cite their sources.
Review reveals losartan overcomes drug resistance by remodeling tumor microenvironments across solid tumors, highlighting its translational potential.
Cancer represents a major global public health challenge, and drug resistance remains a critical barrier to effective clinical management. The highly heterogeneous nature of resistance mechanisms frequently undermines the efficacy of monotherapy, often leading to treatment-related adverse effects or the emergence of secondary resistance. In response, researchers are actively pursuing novel therapeutic strategies aimed at enhancing treatment efficacy and overcoming resistance. Notably, the antihypertensive agent losartan—an angiotensin II type 1 receptor blocker (ARB)—has recently emerged as a promising candidate for repurposing in oncology. Accumulating evidence indicates that losartan can enhance chemotherapy delivery and reverse drug resistance by remodeling the tumor microenvironment. For example, in pancreatic ductal adenocarcinoma, losartan alleviates intratumoral stress through modulation of the extracellular matrix; in ovarian cancer and triple-negative breast cancer, it improves tumor vascular perfusion—both mechanisms contributing to the attenuation of chemotherapy resistance and offering innovative avenues for resistance reversal. This review systematically summarizes the molecular mechanisms underlying losartan's ability to counteract drug resistance and critically evaluates its current and emerging clinical applications. By doing so, it provides a robust theoretical foundation for drug repurposing initiatives and underscores the pivotal role of tumor microenvironment modulation in resistance-targeted therapy. Owing to its favorable safety profile, well-established pharmacokinetics, and low cost, losartan—particularly in combination with conventional chemotherapy or immunotherapy—holds strong translational potential and is poised for rapid clinical implementation. Elucidating the anti-tumor mechanisms and therapeutic utility of losartan carries substantial clinical and translational significance.
No takes yet. Share an insight, caveat, or question.
Han et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: